61 related articles for article (PubMed ID: 21833469)
1. Evaluation of effects caused by differentially spliced Ets-1 transcripts in fibroblasts.
Hahne JC; Fuchs T; Florin A; Edwards D; Pourtier A; Soncin F; Wernert N
Int J Oncol; 2011 Nov; 39(5):1073-82. PubMed ID: 21833469
[TBL] [Abstract][Full Text] [Related]
2. Caspase cleavage of Ets-1 p51 generates fragments with transcriptional dominant-negative function.
Choul-Li S; Leroy C; Leprivier G; Laitem C; Tulasne D; Aumercier M
Biochem J; 2010 Feb; 426(2):229-41. PubMed ID: 20001963
[TBL] [Abstract][Full Text] [Related]
3. Ets-1 p27: a novel Ets-1 isoform with dominant-negative effects on the transcriptional properties and the subcellular localization of Ets-1 p51.
Laitem C; Leprivier G; Choul-Li S; Begue A; Monte D; Larsimont D; Dumont P; Duterque-Coquillaud M; Aumercier M
Oncogene; 2009 May; 28(20):2087-99. PubMed ID: 19377509
[TBL] [Abstract][Full Text] [Related]
4. Identification of ETS-1 target genes in human fibroblasts.
Hahne JC; Okuducu AF; Fuchs T; Florin A; Wernert N
Int J Oncol; 2011 Jun; 38(6):1645-52. PubMed ID: 21424123
[TBL] [Abstract][Full Text] [Related]
5. Dominant-negative inhibition of Ets 1 suppresses tumor growth, invasion and migration in rat C6 glioma cells and reveals differentially expressed Ets 1 target genes.
Sahin A; Vercamer C; Kaminski A; Fuchs T; Florin A; Hahne JC; Mattot V; Pourtier-Manzanedo A; Pietsch T; Fafeur V; Wernert N
Int J Oncol; 2009 Feb; 34(2):377-89. PubMed ID: 19148472
[TBL] [Abstract][Full Text] [Related]
6. Novel identification of the ETS-1 splice variants p42 and p27 in prostate cancer cell lines.
Adler D; Ochsenfahrt J; Fuchs K; Wernert N
Oncol Rep; 2012 May; 27(5):1321-4. PubMed ID: 22307076
[TBL] [Abstract][Full Text] [Related]
7. Dual control of myc expression through a single DNA binding site targeted by ets family proteins and E2F-1.
Roussel MF; Davis JN; Cleveland JL; Ghysdael J; Hiebert SW
Oncogene; 1994 Feb; 9(2):405-15. PubMed ID: 8290253
[TBL] [Abstract][Full Text] [Related]
8. Expression pattern of matrix metalloproteinase and TIMP genes in fibroblasts derived from Ets-1 knock-out mice compared to wild-type mouse fibroblasts.
Hahne JC; Fuchs T; El Mustapha H; Okuducu AF; Bories JC; Wernert N
Int J Mol Med; 2006 Jul; 18(1):153-9. PubMed ID: 16786167
[TBL] [Abstract][Full Text] [Related]
9. Expression of matrix metalloproteinase-9 associated with ets-1 proto-oncogene in rat tubulointerstitial cells.
Naito T; Tanihata Y; Nishimura H; Tanaka T; Higuchi C; Taguchi T; Sanaka T
Nephrol Dial Transplant; 2005 Nov; 20(11):2333-48. PubMed ID: 16046515
[TBL] [Abstract][Full Text] [Related]
10. Identification and expression analysis of alternative transcripts of the mouse GA-binding protein (Gabp) subunits alpha and beta1.
O'Leary DA; Koleski D; Kola I; Hertzog PJ; Ristevski S
Gene; 2005 Jan; 344():79-92. PubMed ID: 15656975
[TBL] [Abstract][Full Text] [Related]
11. Angiogenesis inhibition by transdominant mutant Ets-1.
Nakano T; Abe M; Tanaka K; Shineha R; Satomi S; Sato Y
J Cell Physiol; 2000 Aug; 184(2):255-62. PubMed ID: 10867651
[TBL] [Abstract][Full Text] [Related]
12. Altered Ets transcription factor activity in prostate tumor cells inhibits anchorage-independent growth, survival, and invasiveness.
Foos G; Hauser CA
Oncogene; 2000 Nov; 19(48):5507-16. PubMed ID: 11114728
[TBL] [Abstract][Full Text] [Related]
13. Characterization and functional analysis of the p42Ets-1 variant of the mouse Ets-1 transcription factor.
Lionneton F; Lelièvre E; Baillat D; Stehelin D; Soncin F
Oncogene; 2003 Dec; 22(57):9156-64. PubMed ID: 14668797
[TBL] [Abstract][Full Text] [Related]
14. Involvement of the Ets-1 gene in overexpression of matrilysin in human hepatocellular carcinoma.
Ozaki I; Mizuta T; Zhao G; Yotsumoto H; Hara T; Kajihara S; Hisatomi A; Sakai T; Yamamoto K
Cancer Res; 2000 Nov; 60(22):6519-25. PubMed ID: 11103822
[TBL] [Abstract][Full Text] [Related]
15. The c-ets-1 proto-oncogene has oncogenic activity and is positively autoregulated.
Seth A; Papas TS
Oncogene; 1990 Dec; 5(12):1761-7. PubMed ID: 2284095
[TBL] [Abstract][Full Text] [Related]
16. Ets-1 regulates angiogenesis by inducing the expression of urokinase-type plasminogen activator and matrix metalloproteinase-1 and the migration of vascular endothelial cells.
Iwasaka C; Tanaka K; Abe M; Sato Y
J Cell Physiol; 1996 Dec; 169(3):522-31. PubMed ID: 8952701
[TBL] [Abstract][Full Text] [Related]
17. Transcriptional silencing of ETS-1 efficiently suppresses angiogenesis of pancreatic cancer.
Lefter LP; Dima S; Sunamura M; Furukawa T; Sato Y; Abe M; Chivu M; Popescu I; Horii A
Cancer Gene Ther; 2009 Feb; 16(2):137-48. PubMed ID: 18772901
[TBL] [Abstract][Full Text] [Related]
18. Mitogen-activated protein kinases Erk1/2 and p38 are required for maximal regulation of TIMP-1 by oncostatin M in murine fibroblasts.
Tong L; Smyth D; Kerr C; Catterall J; Richards CD
Cell Signal; 2004 Oct; 16(10):1123-32. PubMed ID: 15240007
[TBL] [Abstract][Full Text] [Related]
19. The Ets-1 transcription factor is up-regulated together with MMP 1 and MMP 9 in the stroma of pre-invasive breast cancer.
Behrens P; Rothe M; Wellmann A; Krischler J; Wernert N
J Pathol; 2001 May; 194(1):43-50. PubMed ID: 11329140
[TBL] [Abstract][Full Text] [Related]
20. The EndoA enhancer contains multiple ETS binding site repeats and is regulated by ETS proteins.
Seth A; Robinson L; Panayiotakis A; Thompson DM; Hodge DR; Zhang XK; Watson DK; Ozato K; Papas TS
Oncogene; 1994 Feb; 9(2):469-77. PubMed ID: 7507230
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
